National Organization for Rare Disorders’ Post

Biocom California recently invited Sapient to contribute an article for its Lifelines Magazine edition focused on innovations in #genetherapy and #celltherapy. https://bit.ly/3KbQEOm While cell- and gene-based treatments are advancing rapidly, spurred by a landmark year of FDA approvals, their development is not without challenges. We discuss how #multiomics for gene and cell therapy can deliver the novel insights needed to realize the incredible therapeutic potential represented in these pipelines today: https://bit.ly/3KbQEOm

Meet the Sannova team at The American Society of Gene & Cell Therapy (ASGCT) annual meeting, booth # 2048. Conference highlights: ✅Cutting-edge Research ✅Networking Opportunities ✅Professional Development Discover new tools, technologies, and resources essential for advancing your work. Stay up-to-date with industry trends, regulations, and potential future directions in cell and gene therapy. Going to ASGCT2024? Introduce yourself in the comments. #biotech, #immunotherapy, #ASGCT2024 #genetherapy #celltherapy

Are you working within cell and gene therapy development? Check out the event from Technology Networks airing Nov 13th, including Ryan Nai's presentation on #plasmid and double-stranded #DNA analyses using the latest kit from #SCIEX, streamlining purity determination and size estimation. 💥 #mRNA #vaccines #SCIEX #CE #capillaryelectrophoresis

Don’t forget to attend our sponsored session at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting on Friday, May 10 from 8-8:30 a.m. EDT. This session will cover how strategic collaborations between #CDMOs and #CROs are addressing industry challenges related to #viralvector production, leading to: - Improved AAV production titer with a significant reduction in cost of goods via high-throughput processes and analytical development - Direct scale-up from bench to 2,000L - Strategies for enhancing % full enrichment during downstream processing - Developing customer-centric analytics for viral vector characterization in development and GMP settings Learn more about this sponsored session here: http://spr.ly/6047jdT23

What is top of mind across cell therapy?... While ISCT, International Society for Cell & Gene Therapy annual meeting is in the rearview, the highlights, key trends, and hurdles remain! We asked stakeholders from companies like Ori Biotech, xcellbio, and uBriGene Biosciences Inc., and investors from AVANT BIO what their key takeaways are. Check it out here: 👉 https://lnkd.in/dEUWbKAi The long and short, you ask? 1️⃣ Manufacturing Innovations and Challenges: The field is rapidly advancing with new automated platforms to address current suboptimal workflows. 2️⃣ Technological Advancements and Excitement: The conference saw multiple launches of new systems, like Ori's IRO®, Cytiva's enhanced Sefia system, and Xcellbio's AVATAR. 3️⃣ Focus on Potency and Data-Driven Processes: There was a strong emphasis on developing better potency assessments and leveraging data-driven processes. Did you attend the conference? What was your key takeaway? Let me know! #celltherapy #pharma #healthcare

Transduction of cells with lentiviruses has not been as convenient and uncomplicated as it can be with the use of Takara Lenti-X Transduction Sponge! The process involves simply adding a mixture of virus and cells onto the sponge and allowing for incubation. The sponge acts as a microfluidic transduction enhancer, bringing cells and viruses in close proximity during incubation and then dissolving upon subsequent centrifugation. As a result, the efficiency of transduction is enhanced with a more convenient and user-friendly method. For more info check related Takara Bio Europe webpages: https://lnkd.in/dwxNmfDb https://lnkd.in/dYr5N7Xc Contact us: info@gen-era.com.tr #lentivirus #transduction #Takara #LentiX #sponge #microfluidic

Unlock the potential of your CAR-T manufacturing with our latest webinar on non-viral gene delivery platforms. Discover how MaxCyte’s innovative solutions can accelerate your development efforts, reduce costs, and lower risks. Featuring presentations by, Steven Feldman, PhD, James Brady, PhD, and Daniel Nguyen. This insightful webinar discusses the use of homology-independent targeted insertion (HITI) to integrate a therapeutically relevant GD2-CAR transgene into the T cell receptor alpha constant (TRAC) locus. This process utilizes nanoplasmid DNA and CRISPR-Cas9 technology in primary human T cells, aiming to enhance the efficiency and effectiveness of CAR-T cell manufacturing. Join us in exploring how our technology, support, and regulatory expertise can light the way to commercialization. Watch the webinar on-demand to learn about the development of a non-viral gene delivery platform for CAR-T manufacturing. https://lnkd.in/eMJDXXAj #HITI #TRAC #DNA #CRISPR #Cas9

In the high-stakes world of gene editing, securing IP is critical. Our latest blog features insights from Cellistic’s Head of IP, Sergei Kurkin on balancing existing patents with new applications to bring innovative therapies to market. Learn about: → CRISPR and gene-editing innovations → Strategies to maintain exclusivity → Navigating complex IP landscapes Click the link to read more and download the full article on Sergei’s expert opinion on securing a strong IP strategy! 📘🔗 #Cellistic #CellTherapy #GeneEditing #IP #IPStrategy

▶️ On-demand Webinar Alert: Our recent webinar, “Unlocking Success in CAR-T Technology Transfer: From Challenges to Seamless Execution,” discusses the essential principles for a smooth CAR-T tech transfer to GMP manufacturing, ultimately accelerating your path to product approval. Watch now: https://lnkd.in/gBFatSCW Hosted by Cell & Gene Therapy Insights, featured panelists – Sara Mills, Senior Principal, Head of Cell Therapy CMC at Dark Horse Consulting Group Inc., Neil Blackburn, PhD, Senior Director, Process and Analytical Development at OmniaBio, Dan Miskimin, Director of MSAT at BrainChild Bio – discuss these key topics: • Mastering the CAR-T cell therapy tech transfer process • Proactively addressing typical obstacles encountered in tech transfer • Real-world case studies on achieving a seamless transition to GMP manufacturing Don't miss this opportunity to gain valuable insights from these industry leaders. #CellandGeneTherapy #TechTransfer #CMC #CellTherapy #GeneTherapy #Webinar

I recently had the pleasure of interviewing Dr. Hao Wu, co-founder and CSO at Full Circles Therapeutics Inc., about their work in non-viral immune cell engineering. Their circular single-stranded DNA technology, GATALYST, is showing promise for CAR-T cell therapy development, achieving up to 70% successful gene integration. Dr. Wu's insights into the potential of this technology to make gene and cell therapies more affordable and accessible are truly inspiring! Head over to CRISPR Medicine News to read the full article! #CRISPR #GeneTherapy #CRISPRMedicineNews #MedicalWriting